Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Technology appraisal guidance
Reference number: TA375
Published:
Tools and resources
Tools and resources to help you put the guidance into practice.